Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-prophylactic-hepatitis-b-virus-vaccines-global-drug-forecast-and-market-analysis-to-2022-market-report.html .
The global hepatitis B virus (HBV) vaccine market value will experience modest growth over the coming years, climbing from approximately $959.9 million in 2012 to $1.19 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.2%, according to a new report from research and consulting firm.
The company’s latest report* states that out of the eight major markets — the US, Canada, France, Germany, Italy, Spain, the UK and Japan — the majority of HBV vaccine sales will take place in the US, which will boast a higher CAGR of 3.4% and expand its market share from 55% to 61.7% during the forecast period. The US will be followed by Canada and the five European countries, with expected CAGRs of 1% and 0.5%, respectively.
According to Researcher, the growth in HBV vaccine sales will result from the launch of Dynavax Technologies’ Heplisav and Sanofi Pasteur MSD’s Hexyon, with peak-year sales anticipated to reach $85 million and $520 million, respectively.
